A funding boost of more than £78 million will help scientists working to develop a potential treatment for motor neurone disease (MND).
Amyotrophic lateral sclerosis (ALS) is the most common form of MND and there is currently no cure for the condition which affects 5,000 people in the UK.
Trace Neuroscience, a new biopharmaceutical company, is working on developing a way to restore the production of a protein that is essential for communication in the brain and spinal cord.
It was founded on the “breakthrough discovery” that loss of the protein called UNC13A is a driver of disease in nearly all people with ALS.
The condition is a rapidly progressive neurodegenerative disorder leading to wasting, paralysis, and eventual death from respiratory failure within three to five years.
Experts suggest that by restoring UNC13A protein levels, healthy communication between nerves and muscle cells impacted by neurodegenerative disease can be re-established thereby slowing the progression of the disease.
Pietro Fratta, professor of cellular and molecular neuroscience at UCL Queen Square Institute of Neurology, said: “UNC13A is critical for neurons to communicate amongst each other and with muscles, and is lost in nearly all ALS cases.
“Being able to re-establish this is groundbreaking.
“This large funding round is pivotal for us to rapidly translate this science into a life-changing medicine and advance our lead program toward the clinic.”
Eric Green, co-founder and chief executive of Trace Neuroscience, said: “Trace Neuroscience was founded on the breakthrough discovery that loss of UNC13A is a driver of disease in nearly all people with ALS.
“We have now brought together academic leaders, experienced drug developers and a leading syndicate of investors committed to urgently turning this discovery into a medicine.”
Trace Neuroscience licensed intellectual property exclusively from UCL as part of the company formation, and the 101 million-dollar USD financing was led by Third Rock Ventures and included participation from Atlas Venture, GV and RA Capital Management.
UCL Business (UCLB) supported the academic team working closely to protect the intellectual property and facilitate the collaboration.
UCLB senior business manager Dr Caitriona O’Rourke, said the funding announcement is a “huge milestone”, but added that it is still very early in the study.
She added: “I’m optimistic about what comes next and look forward to following Trace as it progresses into clinical trials.”
Director of research development at the MND Association Dr Brian Dickie said: “This announcement marks a substantial investment into the further development of this specific area of MND research and will allow what we hope will be the rapid development of a promising new approach to treating motor neurone degeneration, targeting a pathological process which has been linked to 97% of all cases of MND.
“It is really exciting to see the direct impact the MND Association’s support is making in the search for effective treatments for this devastating disease.”
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here